CAH vs CTMX: fair value comparison
Cardinal Health, Inc. and CytomX Therapeutics, Inc. · Updated 2026-10-19
CTMX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CAH currently ranks higher by quality score.
| CAH | CTMX | |
|---|---|---|
| Verdict | Overvalued | No estimate yet |
| Last price | $237.57 | $2.28 |
| 12-month range | $159.16–$254.06 | $2.23–$6.75 |
| Rank by discount to fair value | #75 of 108 Healthcare | — |
| Rank by quality score | #181 of 301 Healthcare | #183 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Declining |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Fairly Valued | — |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: CAH fair value analysis · CTMX fair value analysis